SPONSOR
GlaxoSmithKline
Total Trials
2
Recruiting
2
Phases
Phase 3
Conditions studied: Non-alcoholic Fatty Liver DiseaseMultiple MyelomaNewly Diagnosed Multiple Myeloma
GlaxoSmithKline is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Non-alcoholic Fatty Liver Disease, Multiple Myeloma, Newly Diagnosed Multiple Myeloma.
The trial portfolio spans Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — GlaxoSmithKline
How many clinical trials has GlaxoSmithKline sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by GlaxoSmithKline, of which 2 are actively recruiting participants. These trials cover conditions including Non-alcoholic Fatty Liver Disease, Multiple Myeloma, Newly Diagnosed Multiple Myeloma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does GlaxoSmithKline research focus on?
GlaxoSmithKline clinical trials span Non-alcoholic Fatty Liver Disease, Multiple Myeloma, Newly Diagnosed Multiple Myeloma. The research pipeline includes Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a GlaxoSmithKline clinical trial?
To participate in a GlaxoSmithKline trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all GlaxoSmithKline trials with current recruitment status updated daily.
Clinical Trials by GlaxoSmithKline
NCT07221188 Phase 3
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Non-alcoholic Fatty Liver Disease
NCT06679101 Phase 3
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Multiple Myeloma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology